Bibliographic Details
| Title: |
Associated Myocarditis: A Predictive Factor for Response? |
| Authors: |
Walid Shalata, Nir Peled, Itzhak Gabizon, Omar Abu Saleh, Waleed Kian, Alexander Yakobson |
| Source: |
Case Reports in Oncology, Vol 13, Iss 2, Pp 550-557 (2020) |
| Publisher Information: |
Karger Publishers, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
immune checkpoint inhibitors, myocarditis, melanoma, pembrolizumab, nivolumab, ipilimumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
In the present case report, we aimed to describe 2 cases of myocarditis occurring as serious adverse effects of immune checkpoint inhibitors (ICIs) administered as treatment for metastatic melanoma. We describe 2 female patients: an 81-year-old treated with pembrolizumab and a 55-year-old treated with a combination of nivolumab and ipilimumab. Both patients underwent resection of metastases; while under treatment, both developed myocarditis, most probably as a toxicity from pembrolizumab and nivolumab plus Ipilimumab, respectively. While they achieved complete response, the occurrence of myocarditis as a toxicity of ICIs may have been a predictive sign that the immune system was sufficiently activated by the checkpoint inhibitor therapy to induce complete remission. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1662-6575 |
| Relation: |
https://www.karger.com/Article/FullText/507278; https://doaj.org/toc/1662-6575 |
| DOI: |
10.1159/000507278 |
| Access URL: |
https://doaj.org/article/06830a2fc7f6484f8f2a776ddf0da726 |
| Accession Number: |
edsdoj.06830a2fc7f6484f8f2a776ddf0da726 |
| Database: |
Directory of Open Access Journals |
